Eagle Pharmaceuticals (EGRX): Analyst Day Takeaway - RBC

RBC Capital analyst, Randall Stanicky, reiterated his Outperform rating on shares of Eagle Pharmaceuticals (NASDAQ: EGRX) after the analyst day and is confident in the BENDEKA base and encouraged on the potential for value creation.

Pipeline was the focus at the analyst meeting though there is still a strategic build-out taking place that should enhance value over time. No change to the Outperform rating or $93 PT.

For an analyst ratings summary and ratings history on Eagle Pharmaceuticals click here. For more ratings news on Eagle Pharmaceuticals click here.

Shares of Eagle Pharmaceuticals closed at $79.50 yesterday.

You May Also Be Interested In

• Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
• Freedom Broker Starts Carnival Corporation (CCL) at Buy
• Medtronic, Inc. (MDT) PT Lowered to $101 at Needham